Abstract library

6 results for "Fraenkel".
#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas
Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience
Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
Authors: Kassem S, Glaser B, Barak D, Fraenkel M, ...
#190 Complete Remission in a Patient with Metastatic Type 1 Gastric Carcinoid (GCA1) Treated with a Long-acting Somatostatin Analogue
Introduction: Surgery is the treatment of choice for invasive and metastatic GCA1. Somatostatin analogues have been successfully used in GCA1 patients without signs of malignancy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr merav Fraenkel
#617 Incidence and Geographic Distribution of Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs): A Systematic Review of the Literature
Introduction: Based on the literature, the world-wide incidence of neuroendocrine tumors (NETs) seems to be increasing, however, a systematic literature overview is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Antongiulio Faggiano
#802 Metastatic Type 1 Gastric Carcinoid - A Real Threat or Just a Myth?
Introduction: Metastatic GCA1 are extremely rare and there is no data about their natural history, treatment and prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Dr. Simona Glasberg
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.